Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$12.88 USD
-0.18 (-1.38%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $12.89 +0.01 (0.08%) 7:02 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Day One Biopharmaceuticals, Inc. [DAWN]
Reports for Purchase
Showing records 21 - 40 ( 71 total )
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Continues Its Positive Momentum Toward Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Tovorafenib Continues On the Road Toward Approval in r/pLGG; Reit Buy and $50PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; On Track for Tovorafenib NDA Filing in October 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive FIREFLY-1 ASCO Update Brings Tovorafenib Closer to Approval in pLGG; Reit. Buy and Increasing our PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updated FIREFLY-1 Data at ASCO; Robust Efficacy Across Endpoints
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FIREFLY-1 ASCO Preview-Tovo?s the Total Package; Remain Bullish on Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Crucial (and Exciting) Stretch Ahead for DAWN
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FIREFLY-1/FIREFLY-2 Continues to Burn Bright; Reit Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Encouraging Tovarafinib Data in BRAF-Fusion Melanoma
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FIREFLY-2 Endpoint Change: Different Measuring Sticks, Same Clinical Benefit
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; NDA Submission, Additional FIREFLY-1 Data In 1H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
As Tovorafenib Pushes Forward With NDA in 1H23, We Look Toward Value Outside pLGG; Reit. Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A